Rainer Metternich to head Roche's SMR group
This article was originally published in Scrip
Executive Summary
Roche has appointed Dr Rainer Metternich head of small molecules research, succeeding Klaus Strein who is retiring from Roche. Dr Metternich will lead 800 scientists across Europe and the US. He formerly worked for companies such as Novartis, Schering and Merck & Co, and was most recently chief scientific officer and chief business officer at Caprotec.
You may also be interested in...
Almirall launches Constella in six European markets
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira raises $35m in series B
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis ups public offering to $240m
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.